Current standings of the proton pump inhibitor and clopidogrel co-therapy: Review on an evolving field with the eyes of the gastroenterologist

Digestion

Volumn 81, Issue 1, 2010, Pages 10-15

  Juhász, Márk ^a   Herszényi, László ^a   Tulassay, Zsolt ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Clopidogrel; Gastroprotection; Myocardial infarction; Proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CGT 2168; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; UNCLASSIFIED DRUG;

CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CORONARY STENT; DOSE RESPONSE; DRUG ANTAGONISM; DRUG METABOLISM; DRUG MIXTURE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART REINFARCTION; HUMAN; MEDLINE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; STOMACH PROTECTION; THROMBOCYTE AGGREGATION;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GASTROENTEROLOGY; GASTROINTESTINAL HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; OMEPRAZOLE; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RECURRENCE; TICLOPIDINE;

EID: 72149103011     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000243717     Document Type: Review

References (16)

1. Trenk D: Proton pump inhibitors for prevention of bleeding episodes in cardiac patients with dual antiplatelet therapy - between Scylla and Charybdis? Int J Clin Pharmacol Ther 2009; 47: 1-10.
2. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM: ACCF/ ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118: 1894-1909.
3. Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B, Lafont A, Camoin L, Walter U, Eigenthaler M: Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59: 295-302.
4. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall JF, Boschat J: Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-260.
5. Clarke TA, Waskell LA: The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003; 31: 53-59.
6. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DG, Guyer KE, Bates ER: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107: 32-37. (Pubitemid 36070929)
7. Siller-Matula JM, Lang I, Christ G, Jilma B: Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008; 52: 1557-1563.
8. Ng FH, Lam KF, Wong SY, Chang CM, Lau YK, Yuen WC, Chu WM, Wong BC: Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy. Digestion 2008; 77: 173-177.
9. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS: Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-944.
10. Aubert R, Epstein RS, Teagarden JR, Xia F, Yao J, Desta Z, Skaar T, Flockhart DA: Proton pump inhibitors effect on clopidogrel effectiveness: the Clopidogrel Medco Outcomes Study (abstract 3998). Circulation 2008; 118:S815.
11. Dunn SP, Macaulay TE, Brennan DM, Campbell CL, Charnigo RJ, Smyth SS, Berger PB, Steinhubl SR, Topol EJ: Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO Trial (abstract 3999). Circulation 2008; 118: S815.
12. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, Henry DA, Kopp A, Mamdani MM: A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009 [Epub ahead of print].
13. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B: Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009 157: 148.e1- e5.
14. Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, Schömig A, Kastrati A, von Beckerath N: Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101: 714-719.
15. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ ucm079520. htm - Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix).
16. http://www.emea.europa.eu - EMEA public statement on possible interaction between clopidogrel and proton pump inhibitors. London, 2009, EMEA/328956/2009.